Routine

Hereditary angioedema — long-term prophylaxis & peri-procedural cover

Preventing attacks and covering surgery/dental work in HAE · Allergy / Immunology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Patients with hereditary angioedema (C1-inhibitor deficiency) benefit from long-term prophylaxis when attacks are frequent or severe, and require short-term prophylaxis before procedures that can trigger airway attacks. Modern prophylaxis uses C1-INH concentrate, lanadelumab or berotralstat rather than attenuated androgens.

Figures & algorithms

Clinical features
Clinical features

Red flags

  • Laryngeal attack with voice change or stridor
  • Breakthrough attacks despite prophylaxis
  • Planned airway/dental surgery without arranged cover
  • New low C1q suggesting acquired deficiency / lymphoproliferation
  • Pregnancy (androgens contraindicated; attack frequency may change)

Assessment

Differential diagnosis

  • Acquired C1-inhibitor deficiency
  • ACE-inhibitor angioedema
  • Histaminergic/idiopathic angioedema
  • Normal C1-INH HAE (factor XII / plasminogen mutations)
  • Chronic urticaria with angioedema

Investigations

  • C4 (low between and during attacks)
  • C1-inhibitor antigenic level and function
  • C1q (normal in hereditary, low in acquired)
  • Genetic testing (SERPING1) where diagnosis unclear
  • Baseline attack frequency and severity log to guide prophylaxis

Management

  • Confirm diagnosis with C4 and C1-INH level/function before committing to prophylaxis
  • Ensure every patient has on-demand therapy (icatibant or C1-INH) and a written action plan
  • Offer long-term prophylaxis if attacks are frequent, severe or airway-involving
  • Prefer C1-INH concentrate, lanadelumab or berotralstat over attenuated androgens
  • For procedures with airway/orofacial trauma risk, give short-term prophylaxis before the procedure
  • Arrange on-demand C1-INH/icatibant to be available during and after any procedure
  • Avoid ACE-inhibitors, ARBs and oestrogen-containing contraceptives
  • Refer to a specialist HAE/immunology centre for ongoing management and self-administration training

Drugs & doses

C1 esterase inhibitor concentrate — 20 units/kg IV for acute attacks; 1000 units IV short-term pre-procedure prophylaxis (within 6 h of procedure)
Lanadelumab — 300 mg SC every 2 weeks for long-term prophylaxis
Berotralstat — 150 mg orally once daily for long-term prophylaxis
Icatibant — 30 mg SC as on-demand rescue
Tranexamic acid — 1 g orally three times daily as weak short-term prophylaxis when specific agents unavailable
Danazol — 200 mg orally daily (attenuated androgen, now second-line due to adverse effects)

Disposition

Manage in a specialist HAE service with a self-administration plan; ensure pre-procedure prophylaxis is arranged before any elective airway/dental work.

Complications & pitfalls

  • Fatal laryngeal obstruction during untreated attacks
  • Androgen adverse effects (virilisation, dyslipidaemia, hepatic adenoma)
  • Procedure-triggered attacks without prophylaxis
  • Recurrent abdominal attacks mistaken for surgical abdomen
  • Reduced quality of life and anxiety

Exam pearls

  • Short-term prophylaxis is essential before dental and airway procedures even in well-controlled patients
  • Keep on-demand therapy available regardless of prophylaxis — breakthrough attacks still occur
  • Oestrogens and ACE-inhibitors provoke attacks and should be avoided
  • Androgens are now largely superseded by C1-INH, lanadelumab and berotralstat

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.